biotech · Alzheimer Disease · Major Depressive Disorder · CGTX
Cognition Therapeutics
COGNITION THERAPEUTICS INC
Cognition Therapeutics is a biotech organization headquartered in Purchase, USA. It trades on NYSE under ticker CGTX. Primary therapeutic focus areas include Alzheimer Disease, Major Depressive Disorder, Primary biliary
2500 Westchester Ave, Purchase, New York 10577, US HQ
2007 Founded
32 Employees
Public company Type
CGTX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2500 Westchester Ave, Purchase, New York 10577, US
- Founded
- 2007
- Employees
- 32
- Programs
- 33
- Drugs
- 26
- Patents
- 12
Autobiographical Memory Flexibility (MemFlex) training
Phase 2 · other · Major Depressive Disorder
Autobiographical Memory Flexibility (MemFlex) training for Major Depressive Disorder is a Phase 2 program (other) at COGNITION THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).
Internal code MemFlex to prevent relapse
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- COGNITION THERAPEUTICS INC
- Phase
- Phase 2
- Modality
- other
- Indication
- Major Depressive Disorder
- Status
- completed
- Trials
- 1